^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance.
Published date:
08/29/2020
Excerpt:
NOTCH1 gain-of-function mutations (25%, 3/12 resistant) in the PEST domain were found exclusively in the ibrutinib-resistant cohort associated with the microenvironment-depleted subtype....PD-L1 was significantly downregulated in the ibrutinib-resistant MCL tumors (p = 0.03)...
DOI:
10.1200/JCO.2020.38.15_suppl.8055
